Entry Point Capital, LLC Axsome Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 5,156 shares of AXSM stock, worth $508,794. This represents 0.27% of its overall portfolio holdings.
Number of Shares
5,156
Previous 171
2915.2%
Holding current value
$508,794
Previous $13.8 Million
96.64%
% of portfolio
0.27%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding AXSM
# of Institutions
326Shares Held
37.7MCall Options Held
912KPut Options Held
855K-
Rtw Investments, LP New York, NY4.19MShares$413 Million6.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4MShares$394 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$326 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$233 Million34.46% of portfolio
-
Bvf Inc San Francisco, CA1.05MShares$103 Million2.99% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $4.23B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...